Champlain Investment Partners LLC Sells 82,105 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Champlain Investment Partners LLC lessened its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 4.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,736,240 shares of the medical device company's stock after selling 82,105 shares during the period. Champlain Investment Partners LLC owned about 0.87% of Cooper Companies worth $159,613,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Canada Pension Plan Investment Board boosted its position in shares of Cooper Companies by 6.2% in the fourth quarter. Canada Pension Plan Investment Board now owns 199,170 shares of the medical device company's stock worth $18,310,000 after buying an additional 11,568 shares during the period. Farringdon Capital Ltd. acquired a new stake in Cooper Companies during the 4th quarter worth about $380,000. Guggenheim Capital LLC grew its stake in Cooper Companies by 33.1% during the 4th quarter. Guggenheim Capital LLC now owns 6,808 shares of the medical device company's stock valued at $626,000 after acquiring an additional 1,694 shares in the last quarter. Canada Post Corp Registered Pension Plan purchased a new stake in shares of Cooper Companies in the fourth quarter worth approximately $331,000. Finally, XTX Topco Ltd acquired a new stake in shares of Cooper Companies during the fourth quarter worth approximately $824,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Stock Performance

Shares of NASDAQ COO traded up $0.91 during trading hours on Tuesday, hitting $79.61. 647,733 shares of the stock were exchanged, compared to its average volume of 1,410,405. The firm has a market capitalization of $15.92 billion, a P/E ratio of 40.82, a P/E/G ratio of 2.25 and a beta of 1.01. The Cooper Companies, Inc. has a one year low of $69.81 and a one year high of $112.38. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The company's 50 day moving average is $82.79 and its 200 day moving average is $93.29.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $964.70 million for the quarter, compared to analyst estimates of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. On average, research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on COO. Robert W. Baird cut their target price on shares of Cooper Companies from $117.00 to $107.00 and set an "outperform" rating for the company in a research report on Friday, March 7th. Needham & Company LLC restated a "hold" rating on shares of Cooper Companies in a research note on Friday, March 7th. Piper Sandler reaffirmed an "overweight" rating and issued a $115.00 target price (down from $120.00) on shares of Cooper Companies in a research report on Friday, March 7th. Citigroup lowered their price target on Cooper Companies from $115.00 to $110.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Cooper Companies from $120.00 to $110.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, Cooper Companies has a consensus rating of "Moderate Buy" and an average target price of $110.25.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.